BIOC - バイセプト (Biocept Inc.) バイセプト

 BIOCのチャート


 BIOCの企業情報

symbol BIOC
会社名 Biocept Inc (バイセプト)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 Biocept Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA) assays utilizing a standard blood sample or liquid biopsy. The Company''s Target-Selector offering is based on an internally developed microfluidics-based CTC capture and analysis platform with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications such as breast cancer non-small cell lung cancer (NSCLC) small cell lung cancer (SCLC) gastric cancer colorectal cancer prostate cancer and melanoma.   バイセプトは米国の商品化段階のがん診断会社。標準的な血液サンプルを用いた、独自の循環腫瘍細胞(CTC)及び循環腫瘍DNA(ctDNA)検査を開発・商品化。組織採取が困難な患者から、血液だけでの病理診断が可能となる。異なるタイプのがんと臨床現場においての、がん診断検査の新プラットフォ―ムの開発と技術強化に焦点を当てる。   
本社所在地 5810 Nancy Ridge Drive San Diego CA 92121 USA
代表者氏名 Michael W. Nall マイケル・W・ナル
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-320-8200
設立年月日 35551
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数
url www.biocept.com
nasdaq_url https://www.nasdaq.com/symbol/bioc
adr_tso
EBITDA EBITDA(百万ドル) -22.91521
終値(lastsale) 2.36
時価総額(marketcap) 5385911.76
時価総額 時価総額(百万ドル) 7.30705
売上高 売上高(百万ドル) 3.73582
企業価値(EV) 企業価値(EV)(百万ドル) 6.79433
当期純利益 当期純利益(百万ドル) -21.37632
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Biocept Inc revenues decreased 45% to $1.6M. Net loss increased 24% to $12.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses increase of 31% to $2.1M (expense) Other income decrease from $38K (income) to $30K (expense).

 BIOCのテクニカル分析


 BIOCのニュース

   65 Biggest Movers From Yesterday  2020/11/13 10:02:08 Benzinga
Gainers IMAC Holdings, Inc. (NASDAQ: IMAC ) shares climbed 83.3% to close at $1.52 on Thursday after the company reported the purchase of Lockwood Chiropractic in Webster Groves, Missouri and announced Q3 results. Allied Healthcare Products, Inc. (NASDAQ: AHPI ) jumped 67.2% to close at $7.86. EuroDry Ltd. (NASDAQ: EDRY ) shares gained 58.1% to close at $7.10 after the company swung to a profit in the third quarter. Pyxis Tankers Inc. (NASDAQ: PXS ) gained 40.6% to close at $1.18. Pyxis Tankers is scheduled to release Q3 results on November 13. XPeng Inc. (NYSE: XPEV ) gained 33.4% to close at $44.73 after the company reported Q3 results. Celsius Holdings, Inc. (NASDAQ: CELH ) surged 29% to close at $31.96 after the company reported better-than-expected Q3 results. Electrameccanica Vehicles Corp. (NASDAQ: SOLO ) rose 28.1% to close at $4.83. Li Auto Inc. (NASDAQ: LI ) shares gained 27.3% to close at $31.78. Li Auto reported last week it is recalling some of its Li ONE vehicle models, and the Chinese electric vehicle manufacturer's stock was retreating in reaction.
   Biocept Inc (BIOC) Q3 2020 Earnings Call Transcript  2020/11/13 02:06:39 AlphaStreet
Biocept Inc (NASDAQ: BIOC) Q3 2020 earnings call dated Nov. 12, 2020 Corporate Participants: Bruce Voss — Investor Relations Michael W. Nall — President and Chief Executive Officer Tim Kennedy — Chief Financial Officer and Senior […]
   Biocept Reports Third Quarter 2020 Financial Results  2020/11/12 21:05:00 PR Newswire
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, reports financial results for the…
   Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received  2020/11/12 13:05:00 PR Newswire
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for…
   Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells  2020/11/09 13:05:00 PR Newswire
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded…
   Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells  2020/11/09 13:05:00 PR Newswire
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded…
   Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type  2020/11/05 13:05:00 PR Newswire
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded…
   Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020  2020/11/04 13:00:00 PR Newswire
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020…
   Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold  2020/10/25 04:06:49 The Lincolnian
Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a […]
   Biocept Appoints Samuel D. Riccitelli to its Board of Directors  2020/10/21 12:00:00 PR Newswire
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to its Board of Directors, effective immediately. Mr. Riccitelli is joining the Board ahead of…
   Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Support Biocept Proposal to Authorize the Reverse Split of Common Shares  2020/07/16 12:05:00 PR Newswire
SAN DIEGO, July 16, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Institutional Shareholder…
   Biocept (BIOC) – Why it’s a riskier investment?  2020/07/13 21:46:57 News Alphastreet
Generally, investing in microcap stocks considered to be highly risky and especially it might turn out to be more risky in the current uncertain environment. The returns in microcap stocks might differ depending upon a company’s business model, the opportunities and risks it has, and its ability to perform better in the foreseeable future. Let’s […]
   Biocept awarded Canadian Patent which expands it's patent protection for sensitive detection of cancer cells (NASDAQ:BIOC)  2020/06/30 14:12:28 Seeking Alpha
Biocept (BIOC +3.5%) has been awarded Canadian Patent 2812291, entitled Methods and Reagents for Signal Amplification. This would cover the methods for enh
   Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid  2020/06/30 12:05:00 PR Newswire
/PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable…
   Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims  2020/06/24 12:05:00 PR Newswire
/PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable…

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 バイセプト BIOC Biocept Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)